It uses what’s called an adjuvant, which enhances the body’s immune response to an illness or disease.
In fact Bencard Adjuvant Systems’ technology identical to that found in the company’s highly successful jab for hay fever, Pollinex Quattro.
The latest data will be presented by Allergy Therapeutics' principal scientist, Dr Matthew Heath, at the World Vaccine Congress in Barcelona later Monday.
"Our positive data on adjuvant development is great news in an environment where organisations such as the US National Institutes of Health describe a significant unmet need for adjuvants suitable for use in combination with the growing number of emerging and evolving infectious disease targets,” said the company’s chief scientific officer, Dr Murray Skinner.
“These data support our belief that Bencard Adjuvant Systems has a potentially wide range of applications and we look forward to further results and collaborations, such as this one, in infectious diseases."